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Abstract
Background: Hyperlipidemia is a common disease in China. Although 88.9 % of the Chinese population taking
lipid-lowering medications has already used a statin, only 61.5 % of the population has reached the goal of
low-density lipoprotein cholesterol. Thus, many patients in China seek help from Traditional Chinese Medicine. Yirui
capsules are an innovative Chinese Medicine which are designed to improve the blood lipid state in patients with
hyperlipidemia. However, there is still a lack of high-quality evidence from clinical trials to support the application.
Therefore, we designed a clinical trial to evaluate the safety and efficacy of Yirui capsules for use by patients with
hyperlipidemia.
Methods/design: This is a multicenter, randomized, double-blinded, placebo-controlled trial. Based on lifestyle
modification therapy, eligible patients will randomly be assigned to the Yirui capsule or the placebo group. The
primary outcome is the percentage of participants who reach the goal of 30 % low-density lipoprotein cholesterol
decline at treatment end-point. The secondary outcomes include the changes from baseline to treatment endpoint
in low-density lipoprotein cholesterol, total cholesterol, triglyceride, high-density lipoprotein cholesterol, apolipoprotein
A, apolipoprotein B, non-high-density lipoprotein cholesterol, MOS 36-Item Short-Form Health Survey scoring, total and
individual item scoring of symptomatic grading and quantifying scale, and body mass index.
Discussion: The main ingredients of the Yirui capsule are perilla oil, Folium Ginkgo (Yinxingye), Radix Salviae
miltiorrhizae (Danshen), Fructus Crataegi (Shanzha), Rhizoma Alismatis (Zexie), and Radix Notoginseng (Sanqi), which are
expected to improve the blood lipid state. This randomized placebo-controlled trial will comprehensively evaluate the
effectiveness and safety of Yirui capsules against hyperlipidemia in the hope of providing a new adjunctive Chinese
medicine option for clinical practice in dyslipidemia treatment.
Trial registration: ChiCTR-IOR-15006496. Registered on 29 May 2015.
Protocol version: WXJ.YRJN-HBT-V1.0 (21 Jan 2015).
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Background
Due to the unhealthy lifestyle of modern society, hyperlip-
idemia has become a common disease in China. According
to the latest epidemiological research, more than 300 mil-
lion adults in the Chinese population aged ≥20 years have
a total cholesterol (TC) level ≥5.18 mmol/L and approxi-
mately 200 million people have a low-density lipoprotein
cholesterol (LDL-C) level ≥3.37 mmol/L [1]. Hyperlipid-
emia is considered to be one of the major risk factors for
the development of atherosclerosis and coronary heart dis-
ease (CHD) [2–4]. A recent meta-analysis demonstrated
that a 1 mmol/L LDL-C decrease could result in a 21 %
reduction in risk for a major vascular event [5]. Therefore,
lipid-lowering therapy has significant value in preventing
cardiovascular disease.
Statins are the most common drug used in lipid-lowering
therapy. Of the Chinese population using lipid-lowering
medications, 88.9 % of them used statins. However, only
61.5 % of the population reached the goal of decreased
LDL-C [6]. There may be various reasons for this unsatis-
fied goal attainment. For instance, utilization of moderate/
high-intensity statins is a common method for achieving
the LDL-C goal. However, increasing the intensity of statins
may lead to a high risk of adverse events, which results in
low compliance and thus unsatisfactory goal attainment
[7–9]. Moreover, in China, there is only one category of sta-
tin, simvastatin, which happens to be a low-intensity statin,
on the National Essential Drugs List [10]. The high cost of
other moderate/high-intensity statins may also limit their
usage. Therefore, to help reach their goal attainment, many
patients in China will seek help from Traditional Chinese
Medicine (TCM).
Based on TCM theory, the generation of hyperlipid-
emia has a close relationship with the liver, spleen,
kidney, and diet. The basic pathogenesis is phlegm-
dampness stagnation and blood vessel obstruction by
phlegm and blood stasis. Multiple reasons such as a defi-
ciency of the spleen, over intake of greasy foods, and
stagnation of the liver qi could lead to this pathological
state. Therefore, according to the therapeutic principle
of promoting blood circulation to remove blood stasis
and promoting diuresis to eliminate dampness, the Yirui
capsule is an innovative Chinese Medicine (CM) which
could help hyperlipidemia patients to improve their
blood lipid state.
The major contents of Yirui capsule include perilla oil,
Folium Ginkgo (Yinxingye), Radix Salviae miltiorrhizae
(Danshen), Fructus Crataegi (Shanzha), Rhizoma Alismatis
(Zexie), and Radix Notoginseng (Sanqi). A modern pharma-
cological study showed that the main functional component
of Yirui capsules was alpha-linolenic acid [11]. Recent stud-
ies have illustrated that alpha-linolenic acid could improve
vascular inflammation and endothelial function and be
helpful in secondary prevention of CHD [12–14]. The
lipid-lowering effect of other herbal components has also
been illustrated in animal experiments [15–19]. Possible
mechanisms may relate to limitation of absorption, promo-
tion of the metabolism, and transformation of blood lipids.
As a Chinese Herbal Medicine, Yirui capsules could help
prevent the generation of hyperlipidemia and regulate the
blood lipid level. Two animal experiments have been com-
pleted and demonstrated that Yirui capsules could signifi-
cantly reduce the LDL-C level in hyperlipidemic rat models
[20, 21]. Nevertheless, there is still a lack of high-quality
evidence from clinical trials to support the application. In
the current study, we aim to demonstrate and assess the ef-
ficacy and safety of Yirui capsules in improving hyperlipid-
emia by using a randomized controlled trial (RCT). We
chose simulant Yirui capsules which contained only a pla-
cebo as a comparator so that the actual lipid-lowering effect
of the Yirui capsules could be evaluated.
The study was financially supported by Infinitus (China)
Company Limited and was registered with an identifier
(ChiCTR-IOR-15006496, 29 May 2015) in the Chinese
Clinical Trial Registry (ChiCTR). This funding source had
no role in the design of this study and will not have any
responsibility during its execution, analyses, interpretation
of the data, or decision to submit results.
Methods/design
Study design
This study is conducted as a double-blind, placebo-
controlled trial with two parallel groups to examine the
blood lipid-lowering effect of Yirui capsules. The proto-
col was developed according to Consolidated Standards
of Reporting Trials (CONSORT) statement [22], Stand-
ard Protocol Items: Recommendations for Interventional
Trials (SPIRIT) 2013 [23], and SPIRIT 2013 explanation
and elaboration: guidance for protocols of clinical trials
[24]. We plan to recruit 180 patients from the First Affil-
iated Hospital of Jinan University, Guangdong No. 2
Provincial People’s Hospital, Hexian Memorial Affiliated
Hospital of Southern Medical University, and the Fifth
Affiliated Hospital, Sun Yat-sen University. Clinical in-
vestigators from each center are responsible for screen-
ing eligible participants. After recruitment, participants
are randomly and equally divided into two groups, the
Yirui capsule group and the placebo group. Both arms
will receive lifestyle modification therapy (decreasing the
intake of saturated fatty acids and cholesterol, selecting
foods which could reduce LDL-C, losing weight, increas-
ing regular physical exercise, quitting smoking, limiting
salt intake, etc.). Based on lifestyle modification, the
Yirui group will receive Yirui capsules while the placebo
group will receive simulant capsules. Then, the two arms
will undergo a 24-week treatment and 4-week follow-up
period. According to the China Food and Drug Adminis-
tration guidelines [25], this 24-week treatment period
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was set based on our clinical experience and previous
pilot studies. The participant flowchart is shown in Fig. 1,
and the participant timeline is given in Table 1.
There will be five visits for each participant in week 0,
week 4, week 12, week 24, and week 28. At the first visit,
patients will have their general data recorded and will be
given the prescription. Then, patients will take the
prescription to the specified pharmacy and receive either
Yirui capsules or the placebo. 4 weeks and 12 weeks
after the first visit, patients will come back for clinical
evaluation and medication. Visit 4 is planned for the end
of the treatment period (week 24); at this visit patients
will only receive clinical evaluation. Afterwards, the pa-
tients will stop taking Yirui capsules or the placebo for
Fig. 1 Participant flowchart
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another 4 weeks and then come back for clinical
evaluation.
The study protocol was approved by the ethics commit-
tees of the First Affiliated Hospital of Jinan University,
Guangdong No. 2 Provincial People’s Hospital, Hexian Me-
morial Affiliated Hospital of Southern Medical University,
and the Fifth Affiliated Hospital, Sun Yat-sen University
(Approval Version: LWXJ.YRJN-HBT-V1.0), and informed
consent was obtained from each participant.
Participants
Setting
The trial is conducted at the First Affiliated Hospital of
Jinan University, Guangdong No. 2 Provincial People’s
Hospital, Hexian Memorial Affiliated Hospital of South-
ern Medical University, and the Fifth Affiliated Hospital,
Sun Yat-sen University. All participants are recruited
from the public through the outpatient clinic.
Inclusion criteria
In this study, the inclusion criteria are as follows: (1) age
of 18 to 65 years, both genders; (2) documented blood
lipid test results indicated LDL-C ≥3.37 mmol/L compli-
cated with TC ≥5.18 mmol/L, or triglyceride (TG)
≥1.70 mmol/L, or high-density lipoprotein cholesterol
(HDL-C) <1.04 mmol/L, or both TC ≥5.18 mmol/L and
TG ≥1.70 mmol/L; (3) initial treatment of hyperlipid-
emia; (4) signed informed consent and agreement to
complete all visits, examinations, and treatments.
Exclusion criteria
Patients were excluded for one or more of the following
reasons: (1) TG ≥5.65 mmol/L; (2) combined with
Table 1 Schedule of enrollment, intervention, and assessments
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hypertension, diabetes, or thyroid dysfunction; (3) com-
bined severe primary diseases (i.e., cardiovascular and
cerebrovascular diseases, liver and kidney diseases,
hematopoietic system dysfunction), or malignant tumor,
or mental disorder, or other serious complicated disease;
(4) documented hyperlipidemia-induced target organ
damage (i.e., atherosclerosis and CHD) with need to
maintain treatment to dyslipidemia; (5) secondary hyper-
lipidemia, drug-induced hyperlipidemia, homozygous
hypercholesterolemia; (6) pregnancy; (7) alanine amino-
transferase (ALT) and/or aspartate aminotransferase
(AST) ≥3 times the upper limit of normal (ULN); (8)
creatinine (CREA) ≥1.5 times the ULN; (9) combined
with active peptic ulcer or gastrointestinal hemorrhage;
(10) allergy to components of product or allergic consti-




As mentioned above, every participant should practice
therapeutic lifestyle modification. Specifically, the recom-
mendations include reducing the intake of saturated fatty
acids and cholesterol, choosing foods which could reduce
LDL-C, losing weight, increasing regular physical exercise,
smoking cessation, and limiting salt intake, etc. Diet evalu-
ation should be conducted every week by the participant
him/herself and the information documented in a diet
diary card. The specific items are listed in Table 2.
Chinese Medicine intervention
The Yirui capsule is composed of perilla oil, Folium Ginkgo
(Yinxingye), Radix Salviae miltiorrhizae (Danshen), Fruc-
tus Crataegi (Shanzha), Rhizoma Alismatis (Zexie), and
Radix Notoginseng (Sanqi). The specific Chinese herbal
medicine composition and actions are summarized in
Table 3. The placebo capsule was a simulant Yirui capsule
with a comparable appearance. The main content of the
placebo capsule was starch. By adding food colorants and
flavoring agents, the mixture achieved a color, smell, taste,
and texture comparable to the content of the Yirui capsule.
Participants from both the Yirui group and the placebo
group were informed to take two assigned capsules orally
twice daily for 24 weeks continuously. Both Yirui capsules
and the placebo were packed in sealed plastic bottles (120
capsules each). Only the serial number was printed outside
the package to ensure successful blinding of patients.
Outcomes
Clinical investigators will obtain written informed con-
sent and collect basic data such as gender, age, height,
weight, and medical history at baseline. For safety con-
cerns, besides the basic data, vital signs will be taken
and laboratory examinations conducted, for instance,
blood pressure, heart rate, routine blood tests (e.g., red
blood cell (RBC), white blood cell (WBC), hemoglobin
(Hb), etc.), liver and kidney function tests (e.g., ALT,
AST, CREA, etc.), pregnancy test, and 12-lead electro-
cardiogram (ECG). Except for the pregnancy test, which
only needs to be conducted in the first visit (week 0,
baseline), other tests should be conducted routinely at
every visit during the treatment period (the ECG is not
mandatory at the second visit (week 4)). Also, any ad-
verse events such as abdominal discomfort should be
monitored and recorded during the whole study.
Participants need to receive a blood lipid profile test
which contains the following indexes: TC, TG, HDL-C,
LDL-C, apolipoprotein A (apoA), apolipoprotein B
(apoB), and non-high-density lipoprotein cholesterol
(non-HDL-C). The blood sample should be collected
after at least a 12-hour fast, and the last meal before the
blood sampling should not contain greasy food. In order
to evaluate the health status of participants, the MOS
36-Item Short-Form Health Survey (SF-36) is utilized
[26–28]. In addition, for assessment of clinical symp-
toms, another symptomatic grading and quantifying
scale is applied. Weight monitoring and diet evaluation
are also two aspects that need to be conducted. All par-
ticipants are required to complete the tests and scales
mentioned above at every visit under the guidance and
assistance of the clinical investigators. The results are re-
corded and compared within a group and between
groups before and after intervention.
Yirui capsules are designed to act as an intervention
method for patients with borderline high serum lipid or
an adjunctive choice for patients who could not reach
the serum lipid target with conventional therapy. Based
on the 2013 American College of Cardiology (ACC)/
Table 2 Diet evaluation diary card
Items Scoring
1. Did you eat meat <75 g/day in one recent week? 0 = No, 1 = Yes
2. What kinds of meat did you eat: 0 = lean meat, 1 = fat lean meat, 2 = fat meat, 3 = innards
3. How many eggs did you eat in one recent week? 1 = 0–3 eggs, 2 = 4–7 eggs, 3 =more than 7 eggs
4. How many times did you eat fried food in one recent week? 0 = Not eaten, 1 = 1–4 times, 2 = 5–7 times, 3 =more than 7 times
5. How many times did you eat brioches in one recent week? 0 = Not eaten, 1 = 1–4 times, 2 = 5–7 times
Total
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American Heart Association (AHA) guidelines on the
treatment of blood cholesterol [29], the 2007 Chinese
guidelines on blood lipid abnormality [30], and a previ-
ous TCM clinical trial [31], we set the treatment goal as
a 30 % LDL-C decline compared with baseline after
intervention. Therefore, the primary outcome is the per-
centage of participants who reach the goal at treatment
endpoint (week 24). Secondary outcomes include the
mean changes from baseline at treatment endpoint in
LDL-C, TC, TG, HDL-C, apoA, apoB, non-HDL-C, SF-
36 scoring, total and individual item scoring of symp-
tomatic grading and quantifying scale, and body mass
index (BMI).
Safety and tolerability assessments include collection
of adverse events, physical examination, vital signs, and
the relevant laboratory examination reported previously.
Clinical investigators should observe any adverse events
that occur during the clinical trial, including abnormal
symptoms and signs, unusual laboratory indicators, etc.
Whether or not the adverse event is related to the inter-
ventions, investigators are required to record it compre-
hensively, including onset time, related symptoms and
signs, extent, duration, laboratory indexes, treatment, re-
sult, and follow-up. In addition, drug combinations
should also be documented in order to analyze the
correlation between adverse events and experimental
products.
Assignment and blinding
Block randomization is conducted in a 1:1 ratio to re-
ceive either Yirui capsules or the placebo. As this study
is a multicenter study, blocked randomization is con-
ducted for each center. The randomization sequence
table generated by Statistical Analysis System (SAS)
Version 9.2 was provided by a specific statistical re-
searcher who does not participate in the clinical trial.
The statistical researcher randomly distributes the num-
ber to the research products. The random numbers are
kept in opaque sealed envelopes and sent to research
centers. Afterwards, clinical investigators randomly as-
sign the random number based on enrollment order and
provide the corresponding drug. Choosing the number
intentionally is strictly forbidden. The random number
is fixed during the whole study. The blinding base con-
taining the randomization sequence, parameters of se-
quence, and random number is sealed in duplicate and
reserved by the principal investigator and product regis-
tration applicant. Patients and clinical investigators can
only be aware of the individual random number. Treat-
ment assignments are not exposed and are blinded to
patients and any clinical investigators involved in this
trial until the entire study is completed. At the last visit,
all participants and clinical investigators will finish a
questionnaire about which treatment (Yirui capsule
group or placebo group) the patients received to assess
the success of blinding. Emergency letters containing
random number and treatment assignment would also
be prepared by a specific statistical researcher. Code
breaks are only allowed in emergency situations when
practical intervention is compulsory for further manage-
ment of the participant.
Sample size calculation
The sample size calculation was based on the primary
outcome measure. Previous studies of Chinese herbal
medicine (CHM) on hyperlipidemia had detected a dif-
ference of at least 20 % between Yirui capsule and pla-
cebo. Assume that placebo effect is about 10 %. The
sample size in each group was determined by using the
formula derived by Whitley et al. [32]:
n ¼ p1 1−p1ð Þ þ p2 1−p2ð Þ½ 
p1−p2ð Þ2
 Cp; power
For type I: α = 0.05, β = 0.10; power (1-β) = 90 %; p1 =
10 %, p2 = 30 %; and C p, power = 10.5; the two-tailed level
Table 3 Composition and action of Chinese herbal medicine in Yirui capsule
Ingredients Action
Folium Ginkgo TCM: Promoting blood circulation to remove blood stasis and stop pain
Pharmaceutical study: (1) cardiovascular protective effect, (2) hypolipidemic effect, (3) effect of antagonizing lipid
peroxide, (4) effect of improving cerebral circulation
Radix Salviae miltiorrhizae TCM: Promoting blood circulation to remove blood stasis, cooling blood and treating boils, tranquilizing mind
Pharmaceutical study: (1) cardiovascular protective effect, (2) hypotensive effect, (3) hypolipidemic effect,
(4) anti-inflammatory effect, (5) anti-coagulation effect
Fructus Crataegi TCM: Removing food retention and flatulence, promoting blood circulation to remove blood stasis
Pharmaceutical study: (1) gastrointestinal regulation effect, (2) cardiovascular protective effect, (3) hypotensive effect,
(4) hypolipidemic effect
Rhizoma Alismatis TCM: Eliminating dampness and diuresis, purging heat
Pharmaceutical study: (1) diuretic effect, (2) hypolipidemic effect, (3) anti-allergic effect, (4) anti-inflammatory effect
Radix Notoginseng TCM: Hemostatic elimination of stagnation, promoting blood circulation to stop pain
Pharmaceutical study: (1) Anti-coagulation effect, (2) hematopoiesis effect, (3) cardiovascular protective effect,
(4) analgesic effect, (5) anti-inflammatory effect
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α and power were set at 0.05 and 80 %, respectively.
Seventy-five subjects were needed in each group. Esti-
mating about 20 % dropouts, the number of each group
was 90, and a total of 180 subjects were needed for this
study.
Statistical analysis
All effectiveness and safety evaluations will be conducted
according to the intention-to-treat (ITT) principle. The
last-observation-carried-forward method will be applied
to deal with missing values. SAS (Version 9.2) will be
utilized to analyze the data, and the statistical signifi-
cance is defined as a two-sided P value of <0.05. For
measurement data, the mean, standard deviation (SD),
maximum, minimum, P25, median, and P75 will be re-
ported. For paired measurement data, the mean differ-
ence, SD, and confidence interval (CI) will also be
reported. As to enumeration data and ranked data, fre-
quency distribution and corresponding percentage are
compulsory. Baseline data of the two arms (e.g., demo-
graphic data) will undergo descriptive and inferential
analyses. Intra-group efficacy comparisons before and
after the treatment will be conducted by using the paired
t test or Wilcoxon signed rank test for quantitative vari-
ables and the chi-squared test for qualitative variables.
Efficacy difference between groups will be assessed with
the utilization of the two-sample t test or corresponding
non-parameter methods for quantitative variables, the
chi-squared test for qualitative variables, and the Wil-
coxon rank sum test for rank variables. For the primary
outcome, the mean difference with two-sided 95 % CI
will be reported. Statistic effectiveness is defined as the
lower limit of 95 % CI above 0. Clinical effectiveness
needs to be assessed after combining with clinical sig-
nificance. For the consideration of the multicenter char-
acter, a covariance model is used to evaluate the center
effect for the primary variable. Other secondary out-
comes will take no account of the center effect. In
addition, the chi-squared test will be utilized to analyze
the rate of adverse events between the two arms. A table
will be generated to enumerate and describe the charac-
ters of all adverse events during the study.
Data collection and handling of withdrawal and dropout
In this 28-week clinical trial, it is compulsory for partici-
pants to take experimental medication for a continuous
24 weeks, be present at five assessment visits, conduct sev-
eral blood tests, finish certain scales, complete a diet evalu-
ation diary card, and stop taking other lipid-lowering
medication and drugs with relevant herbal ingredients. Spe-
cially assigned individuals will record the original data, and
the relevant materials will be placed on file based on nu-
merical order at the specified site appropriately. Only prin-
cipal investigators and clinical investigators have the right
to examine the documents. Original documents should be
preserved at least 5 years after finishing the study.
For maximum compliance of patients, we require all
researchers and doctors to obey the following rules.
Firstly, all researchers should obey the principle of in-
formed consent and help participants understand the re-
quirements of the study. Secondly, researchers need to
monitor the compliance of patients through the dose
counting method. Thirdly, all doctors should ask pa-
tients to bring all medications to every visit to examine
and record any drug combinations. Moreover, investiga-
tors will contact the participant to remind them of the
visit three days in advance and to inform them of the
specific arrangements for the next visit. For patients
who do not respond to the medication or cannot take
medication on time, increasing the frequency of the
follow-up visits is compulsory.
Participants can quit the study if they experience: (1)
severe adverse effect(s), (2) hypersensitivity towards the
research medication, or (3) aggravation of disease. The
whole research plan will be terminated for the following
circumstances: (1) presence of serious adverse events re-
lated to the research medication, (2) no practical value
findings of the medication during the treatment, or (3)
completion of all follow-up assessments.
Discussion
Hyperlipidemia is now becoming a frequent illness in clin-
ical practice. An overwhelming majority of patients choose
statins as the first option of lipid-lowering therapy. Re-
cently, considering the fact that the LDL-C theory of
“lower is better” has been illustrated repeatedly [5, 33, 34],
the latest guidelines point out that lipid-lowering therapy
should select high- or moderate-intensity statins [2]. How-
ever, high-intensity statins also bring a high risk of adverse
events [35]. The study of Preiss et al. even found that in-
tensive statin therapy would increase the risk of new onset
diabetes compared with moderate statin therapy [36].
Moreover, for the Chinese population, it has been re-
ported that the pharmacokinetic characteristics of rosu-
vastatin in Asian people are different than in Caucasians,
which may lead to the drug accumulation and increase
the risk of adverse events [37]. Therefore, ways of attain-
ing the LDL-C goal with relatively low-intensity statins
combined with other kinds of drugs has become a popular
research topic.
TCM has been used for thousands of years to treat dis-
eases. Many classic formulas have been modified by mod-
ern techniques and applied in clinical practice. The Yirui
capsule is a kind of CM used to regulate blood circulation.
The main ingredients are perilla oil, Folium Ginkgo
(Yinxingye), Radix Salviae miltiorrhizae (Danshen), Fruc-
tus Crataegi (Shanzha), Rhizoma Alismatis (Zexie), and
Radix Notoginseng (Sanqi). In TCM theory, these
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components have the effect of promoting blood circula-
tion and dispelling dampness; blood stasis and dampness
provide the crucial pathogenesis of hyperlipidemia in the
TCM concept. Moreover, a recent study proved that pe-
rilla oil was effective in improving the blood lipid profile
of patients with hyperlipidemia [38]. The lipid-lowering
effect of other Chinese Herbal Medicine ingredients was
also demonstrated in animal experiments [15–19]. There-
fore, by conducting this randomized placebo-controlled
trial, we hope to verify the lipid-lowering effect of Yirui
capsules and thus provide a new adjunctive option for
clinical practice.
The clinical trial protocol is the base of the whole study.
It plays a crucial role through study preparing, proceeding,
reporting, and evaluation. This protocol has been devel-
oped according to CONSORT statement [21], SPIRIT
2013 [22], and the SPIRIT 2013 explanation and elabor-
ation: guidance for protocols of clinical trials [23] in order
to establish an appropriate standard for scientific, ethical,
and safety issues of the study.
In conclusion, the results of the study are expected to
provide exact efficacy and safety evidence of Yirui cap-
sules in treating hyperlipidemia. This may help provide
clinicians with another option for adjunctive lipid-
lowering treatments based on statins.
Trial status
At the time of manuscript submission, patients are being
recruited, and no one has yet completed the treatment.
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